Dirk Garmann

688 total citations
30 papers, 552 citations indexed

About

Dirk Garmann is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Molecular Biology. According to data from OpenAlex, Dirk Garmann has authored 30 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 8 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Dirk Garmann's work include Atrial Fibrillation Management and Outcomes (5 papers), Hemophilia Treatment and Research (5 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). Dirk Garmann is often cited by papers focused on Atrial Fibrillation Management and Outcomes (5 papers), Hemophilia Treatment and Research (5 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). Dirk Garmann collaborates with scholars based in Germany, United States and Sweden. Dirk Garmann's co-authors include Ulrich Jaehde, Felix Kratz, André Warnecke, Ganna V. Kalayda, Alexander Solms, Iduna Fichtner, Anita Shah, Bart A. Ploeger, Jörg Lippert and Thomas Eißing and has published in prestigious journals such as Journal of Controlled Release, European Heart Journal and Clinical Pharmacology & Therapeutics.

In The Last Decade

Dirk Garmann

30 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dirk Garmann Germany	13	137	135	130	109	82	30	552
Celeste B. Burness New Zealand	17	106 0.8×	65 0.5×	200 1.5×	56 0.5×	44 0.5×	29	727
Kakali Ghoshal India	12	55 0.4×	85 0.6×	132 1.0×	78 0.7×	22 0.3×	22	737
Sean X. Gu United States	11	61 0.4×	59 0.4×	152 1.2×	61 0.6×	79 1.0×	27	658
R. Emanuele Italy	12	73 0.5×	58 0.4×	95 0.7×	72 0.7×	71 0.9×	29	539
Robert B. Fairweather United States	15	37 0.3×	127 0.9×	164 1.3×	108 1.0×	101 1.2×	24	702
Upendra Marathi United States	10	47 0.3×	157 1.2×	144 1.1×	21 0.2×	17 0.2×	15	467
Tsukasa Ishihara Japan	15	31 0.2×	242 1.8×	164 1.3×	93 0.9×	109 1.3×	45	600
H. Narjes Germany	11	114 0.8×	69 0.5×	111 0.9×	55 0.5×	75 0.9×	17	461
Anna Remková Slovakia	12	20 0.1×	123 0.9×	45 0.3×	41 0.4×	56 0.7×	31	353
Yuhan Qin China	14	44 0.3×	123 0.9×	424 3.3×	32 0.3×	33 0.4×	48	904

Countries citing papers authored by Dirk Garmann

Since Specialization

Citations

This map shows the geographic impact of Dirk Garmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Garmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Garmann more than expected).

Fields of papers citing papers by Dirk Garmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Garmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Garmann. The network helps show where Dirk Garmann may publish in the future.

Co-authorship network of co-authors of Dirk Garmann

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Garmann. A scholar is included among the top collaborators of Dirk Garmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Garmann. Dirk Garmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morcos, Peter N., et al.. (2024). Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen. Clinical Pharmacology & Therapeutics. 115(5). 1092–1104. 2 indexed citations

Wellhagen, Gustaf J., Ashraf Yassen, Dirk Garmann, et al.. (2024). Evaluation of covariate effects in item response theory models. CPT Pharmacometrics & Systems Pharmacology. 13(5). 812–822. 2 indexed citations

Eißing, Thomas, Sebastiaan C. Goulooze, Paul van den Berg, et al.. (2023). Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD. Diabetes Obesity and Metabolism. 26(3). 924–936. 8 indexed citations

Morcos, Peter N., Rolf Burghaus, Jonathan Moss, et al.. (2023). Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. Clinical and Translational Science. 16(7). 1197–1209. 3 indexed citations

Solms, Alexander, et al.. (2023). Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches. Clinical Pharmacokinetics. 62(11). 1639–1648. 1 indexed citations

Morcos, Peter N., Jonathan Moss, Rupert Austin, et al.. (2023). Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1666–1686. 3 indexed citations

Goulooze, Sebastiaan C., Meike Brinker, Amer Joseph, et al.. (2021). Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clinical Pharmacokinetics. 61(3). 451–462. 23 indexed citations

Berg, Paul van den, Roland Heinig, Amer Joseph, et al.. (2021). Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. Clinical Pharmacokinetics. 61(3). 439–450. 14 indexed citations

Klein, Dagmar, Joachim Grevel, Rupert P. Austin, et al.. (2021). Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Clinical Pharmacokinetics. 60(11). 1407–1421. 16 indexed citations

10.

Solms, Alexander, Stefan Willmann, Theodore E. Spiro, et al.. (2020). Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 50(1). 1–11. 4 indexed citations

11.

Solms, Alexander, Stefan Willmann, Theodore E. Spiro, et al.. (2020). Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 50(1). 12–19. 11 indexed citations

12.

Solms, Alexander, et al.. (2019). Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients. Haematologica. 105(5). 1443–1453. 19 indexed citations

13.

Solms, Alexander, Alfonso Iorio, Maurice J. Ahsman, et al.. (2019). Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clinical Pharmacokinetics. 59(5). 605–616. 12 indexed citations

14.

Heinig, Roland, Henk‐Jan Drenth, Amer Joseph, et al.. (2019). Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clinical Pharmacokinetics. 59(3). 359–370. 26 indexed citations

15.

Solms, Alexander, et al.. (2019). Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII. CPT Pharmacometrics & Systems Pharmacology. 8(12). 894–903. 8 indexed citations

16.

Solms, Alexander, Scott D. Berkowitz, Anne Hermanowski‐Vosatka, et al.. (2019). Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. CPT Pharmacometrics & Systems Pharmacology. 8(11). 805–814. 8 indexed citations

17.

Shah, Anita, et al.. (2016). Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. Clinical Pharmacokinetics. 56(9). 1045–1055. 28 indexed citations

18.

Garmann, Dirk, M. Galanski, G. Weber, et al.. (2011). Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?. Journal of Inorganic Biochemistry. 105(5). 709–717. 35 indexed citations

19.

Rotte, Anand, et al.. (2010). Effect of Extracellular ATP on Cisplatin-Induced Cytotoxicity in Human Ovarian Carcinoma Cells. Chemotherapy. 56(1). 1–8. 8 indexed citations

20.

Garmann, Dirk, André Warnecke, Ganna V. Kalayda, Felix Kratz, & Ulrich Jaehde. (2008). Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. Journal of Controlled Release. 131(2). 100–106. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact